Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Literature DB >> 28187281

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Paul Workman¹, Giulio F Draetta², Jan H M Schellens³, René Bernards⁴.

Abstract

The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.

Entities: Chemical

Mesh：

Substances：
Antineoplastic Agents

Year: 2017 PMID： 28187281 DOI： 10.1016/j.cell.2017.01.034

Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582

Keyword Cloud
Cited

23 in total

1. The Cancer Drugs Fund in Practice and Under the New Framework.

Authors: Celia Sabry-Grant; Kinga Malottki; Alexander Diamantopoulos
Journal: Pharmacoeconomics Date: 2019-07 Impact factor: 4.981

Review 2. Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Authors: Abhijit Pal; Rajiv Shinde; Manuel Selvi Miralles; Paul Workman; Johann de Bono
Journal: Nat Rev Clin Oncol Date: 2021-03-24 Impact factor: 66.675

Review 3. Tumor targeting via EPR: Strategies to enhance patient responses.

Authors: Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal: Adv Drug Deliv Rev Date: 2018-07-19 Impact factor: 15.470

Review 4. Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung
Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316

5. Leveraging Human Genetics to Guide Cancer Drug Development.

Authors: Ben Kinnersley; Amit Sud; Elizabeth A Coker; Joseph E Tym; Patrizio Di Micco; Bissan Al-Lazikani; Richard S Houlston
Journal: JCO Clin Cancer Inform Date: 2018-12

6. Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia.

Authors: Sofia Merajver; Sameer Phadke; Matthew Soellner
Journal: Trans Am Clin Climatol Assoc Date: 2017

7. Apoptotic and antioxidant effects in HCT-116 colorectal carcinoma cells by a spiro-acridine compound, AMTAC-06.

Authors: Sâmia Sousa Duarte; Daiana Karla Frade Silva; Thaís Mangeon Honorato Lisboa; Rawny Galdino Gouveia; Camyla Caroliny Neves de Andrade; Valgrícia Matias de Sousa; Rafael Carlos Ferreira; Ricardo Olimpio de Moura; Joilly Nilce Santana Gomes; Patricia Mirella da Silva; Fátima de Lourdes Assunção Araújo de Azevedo; Tatjana S L Keesen; Juan Carlos Ramos Gonçalves; Leônia Maria Batista; Marianna Vieira Sobral
Journal: Pharmacol Rep Date: 2022-03-17 Impact factor: 3.024